HER-2 Protein Overexpression clinical trials at University of California Health
2 in progress, 1 open to eligible people
ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
at UCLA
Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Sorry, currently not accepting new patients, but might later
This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.
at UCSD
Our lead scientists for HER-2 Protein Overexpression research studies include Nicolaos J Palaskas, MD, PhD.
Last updated: